Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
FY2025 total revenues .4B (+2%). Core HIV franchise delivered with Biktarvy .3B (+7%), Descovy .8B (+31%). Yeztugo (lenacapavir PrEP) launched — first 2x/year HIV prevention therapy. Cell therapy decl...